Fingerprint
Dive into the research topics of 'Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma'. Together they form a unique fingerprint.- Sort by
- Weight
- Alphabetically
Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma
John M. Kirkwood, Paul Lorigan, Peter Hersey, Axel Hauschild, Caroline Robert, David McDermott, Margaret A. Marshall, Jesus Gomez-Navarro, Jane Q. Liang, Cecile A. Bulanhagui
Research output: Contribution to journal › Article › peer-review